- Home
- SABR vs ORIC Comparison
SABR vs ORIC Comparison
Compare SABR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | ORIC |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.4M | 861.3M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SABR | ORIC |
|---|---|---|
| Price | $2.21 | $13.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $1.50 | ★ $19.73 |
| AVG Volume (30 Days) | ★ 3.9M | 1.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,866,956,000.00 | N/A |
| Revenue This Year | $7.51 | N/A |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $7.23 |
| 52 Week High | $2.30 | $14.93 |
Technical Indicators
Market Signals| Indicator | SABR | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 70.33 |
| Support Level | $1.58 | $10.45 |
| Resistance Level | N/A | $14.15 |
| Average True Range (ATR) | 0.16 | 0.91 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 87.20 | 89.96 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.